Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
China flag China · Delayed Price · Currency is CNY
5.10
+0.35 (7.37%)
Sep 30, 2026, 3:04 PM CST

SHE:002581 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
297.97274.74355.66425.78356.18397.44
Other Revenue
0.10.074.754.010.95.27
298.07274.81360.41429.79357.08402.71
Revenue Growth
35.24%-23.75%-16.14%20.36%-11.33%45.47%
Cost of Revenue
215.82152.9287.6793.2976.6485.83
Gross Profit
82.25121.89272.74336.5280.44316.88
Selling, General & Admin
230.96269.38336.65453.3426.21477.76
Research & Development
16.2218.8725.3759.827.2938.44
Other Operating Expenses
6.456.16.316.786.246.83
Operating Expenses
274.11311.4363.6492.32456.02520.83
Operating Income
-191.86-189.51-90.86-155.81-175.57-203.95
Interest Expense
-1.96-1.12-0.18-9.06-9.41-6.88
Interest & Investment Income
19.6621.167.28174.463.023.75
Earnings From Equity Investments
----217.45471.94
Currency Exchange Gain (Loss)
-0-00-0-0.01
Other Non Operating Income (Expenses)
0.660.180.28-9.880.22-6.68
EBT Excluding Unusual Items
-173.51-169.35-23.49-0.2935.72258.18
Gain (Loss) on Sale of Investments
-4.19--18.65---
Gain (Loss) on Sale of Assets
3.823.771.16-6.330.05-0.15
Asset Writedown
-20.38-20.24-69.64-293.88-13.61-0.48
Legal Settlements
---33.27--15.49-
Other Unusual Items
8.8310.28-2.29-12.766.0521.05
Pretax Income
-185.44-175.53-146.18-313.2512.72278.6
Income Tax Expense
-7.7-14.7-3.348.8913.58-0.09
Earnings From Continuing Operations
-177.74-160.83-142.84-322.14-0.86278.69
Minority Interest in Earnings
33.2944.555.52-10.32-13.82-7.69
Net Income
-144.45-116.28-137.31-332.46-14.68271
Net Income to Common
-144.45-116.28-137.31-332.46-14.68271
Net Income Growth
------
Shares Outstanding (Basic)
660660660660658660
Shares Outstanding (Diluted)
660660660660658660
Shares Change
-0.07%-0.04%0.01%0.22%-0.21%-0.00%
EPS (Basic)
-0.22-0.18-0.21-0.50-0.020.41
EPS (Diluted)
-0.22-0.18-0.21-0.50-0.020.41
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-347.31-433.43-15.56-40.82-85.95-106.86
Free Cash Flow Per Share
-0.53-0.66-0.02-0.06-0.13-0.16
Gross Margin
27.59%44.36%75.67%78.30%78.54%78.69%
Operating Margin
-64.37%-68.96%-25.21%-36.25%-49.17%-50.64%
Profit Margin
-48.46%-42.31%-38.10%-77.35%-4.11%67.29%
Free Cash Flow Margin
-116.52%-157.72%-4.32%-9.50%-24.07%-26.53%
EBITDA
-153.32-151.92-49.7-87.43-110.63-144.38
EBITDA Margin
-51.44%-55.28%-13.79%-20.34%-30.98%-35.85%
D&A For EBITDA
38.5437.5941.1668.3964.9559.57
EBIT
-191.86-189.51-90.86-155.81-175.57-203.95
EBIT Margin
-64.37%-68.96%-25.21%-36.25%-49.17%-50.64%
Effective Tax Rate
----106.75%-
Revenue as Reported
298.07274.81360.41429.79357.08402.71